Business Wire

CA-DENODO

2.9.2020 09:02:09 CEST | Business Wire | Press release

Share
Adoption of Denodo Coronavirus Data Portal Initiative Grows as More Customers and Partners Use It to Fight and Minimize the Impact of COVID-19

Denodo , the leader in data virtualization, today announced increased adoption of its Coronavirus Data Portal (CDP), an open, cooperative effort that utilizes data virtualization to unify critical datasets originally exposed in different formats from multiple sources and countries. Originally developed in March during early onset of the pandemic, Denodo has combined and unified COVID-19 related intelligence and made it available to data consumers such as data scientists, analysts, and researchers who are leveraging the information to find solutions to this global disease. For more information, and to participate in the effort, visit https://www.coronavirusdataportal.com .

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200902005272/en/

“In an effort to measure and monitor the health of our employees, we needed to create a way for them to tell us about their own health and to provide the clinical teams and leadership with details on who is healthy and who is not before coming to work,” said Mahendra Parasmal, Sr. Information Architect at Spectrum Health . “Denodo provides us with the ability to connect self-purported health data provided by employees via an online survey with employee demographics, employee hierarchy, badge system & Active Directory data virtually. This delivers wellness information in near real-time without having to Extract, Transform & Load the data physically from source systems or run batch incremental loads. As a result, we have been able to speed up our overall build time by at least 3x and deliver the end result in weeks instead of months.”

Free of charge to participants, the Coronavirus Data Portal enables organizations and institutions to share their individual data sets that Denodo integrates and offers to the broader community for consumption via the data platform. It also allows members to integrate and curate these data sets so they can augment their own COVID-19 initiatives. As of today, there are 64 sources, 220 datasets, and 441 views offered on CDP.

“I can personally attest to how our company was able to leverage Denodo’s Coronavirus Data Portal having developed a COVID-19 virtual hub that provides reports based on data science and pmOne Share ,” said Dr. Norman Bernhardt, Head of Digital Solutions R&D, pmOne . “pmOne Share Cockpit aggregates existing and established reporting solutions and provides advanced filtering capabilities, which data scientists can use to develop algorithms to analyze global news flows, the results of which are displayed in a dashboard.”

More specifically, Denodo’s CDP is being used to:

  • Search the Curated Datasets: Coronavirus Data Portal offers a catalog of the curated data sets - both uploaded and curated by Denodo data stewards and those contributed by users of the data portal. This allows users to search the available data sets and find the data relevant to them such as details about the spread of the disease, school closures, financial impact, etc. It also enables them to drill deeper to view details about a particular data set and its relationship with other ones.
  • Enhance Dashboard BI Tools with Integrated Data Portal: CDP supports BI tools such as Power BI, Tableau and others so participants can connect to the data portal and generate smart visualizations. Users can use these tools to easily create new customized reports of the integrated data.
  • Extend Data integration Using API Service/Downloadable CSV Datasets: Lets users further integrate their application with the Coronavirus Data Platform, utilizing it as an API service layer. This enables users to access the curated data sets in a variety of views and is an option that is growing significantly as more and more multi-faceted data is added from across the globe.
  • Contribute to the Initiative: The Coronavirus Data Portal is an open platform, which permits users to contribute their own data sets to the initiative. It suggests data sources that should be added to the Data Portal and Denodo’s data steward team will review the data and usage permissions to determine if it’s appropriate to be uploaded. Alternatively, they can create new data sets by combining the Coronavirus Data Portal data with their own data and share this new data set with other Data Portal users.

“While our data stewards and data engineers have been working behind the scenes to add more data sets to the Coronavirus Data Portal, we have also been getting some great suggestions from the user community. Based on suggestions, we’ve added COVID-19 forecast data, real-time information about how many are infected and where, school closures, global news as they are published, and much more,” said Angel Viña, CEO and Founder at Denodo. “Contributing data sets - either through suggestions or by creating derived data sets - will continue the growth of the Coronavirus Data Portal and enhance the value that fellow users are getting from using the data. This continued growth will provide more varied and richer data for all of us to use and share in our efforts to combat this deadly pandemic.”

Please Tweet: News: #datavirtulization provider @denodo offers complimentary #coronavirus data portal to unify #datasets and information to fight #COVID19

About Denodo

Denodo is the leader in data virtualization providing agile, high performance data integration, data abstraction, and real-time data services across the broadest range of enterprise, cloud, big data, and unstructured data sources at half the cost of traditional approaches. Denodo’s customers across every major industry have gained significant business agility and ROI by enabling faster and easier access to unified business information for agile BI, big data analytics, Web, cloud integration, single-view applications, and enterprise data services. Denodo is well-funded, profitable, and privately held. For more information, visit http://www.denodo.com or call +1 877 556 2531 / +44 (0) 20 7869 8053.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse

Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release

Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye